Prescriber's Corner
For access to the full length article, please sign in.
Monoclonal Antibodies in the Treatment of Multiple Myeloma
Charise Gleason,(1) MSN, NP-BC, AOCNP®, Hollie Devine,(2) MSN, ANP-BC, Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, Deborah Doss,(4) RN, OCN®, and Sandra Kurtin,(5) RN, MSN, AOCN®, ANP-C, on behalf of the International Myeloma Foundation Nurse Leadership Board
1Winship Cancer Institute of Emory University, Atlanta, Georgia; 2The Ohio State University Medical Center, Columbus, Ohio; 3Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio; 4Dana-Farber Cancer Institute, Boston, Massachusetts; 5The University of Arizona Cancer Center, Tuscon, Arizona
Charise Gleason, MSN, NP-BC, AOCNP®, Winship Cancer Institute of Emory University, 1365 Clifton Road, NE, Atlanta, GA 30322. E-mail: charise.gleason@emoryhealthcare.org
Authors’ disclosures of potential conflicts of interest are found at the end of this article
J Adv Pract Oncol 2016;7:53–57 | doi: 10.6004/jadpro.2016.7.2.14 | © 2016 Harborside Press®
1Winship Cancer Institute of Emory University, Atlanta, Georgia; 2The Ohio State University Medical Center, Columbus, Ohio; 3Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio; 4Dana-Farber Cancer Institute, Boston, Massachusetts; 5The University of Arizona Cancer Center, Tuscon, Arizona
Charise Gleason, MSN, NP-BC, AOCNP®, Winship Cancer Institute of Emory University, 1365 Clifton Road, NE, Atlanta, GA 30322. E-mail: charise.gleason@emoryhealthcare.org
Authors’ disclosures of potential conflicts of interest are found at the end of this article
J Adv Pract Oncol 2016;7:53–57 | doi: 10.6004/jadpro.2016.7.2.14 | © 2016 Harborside Press®
For access to the full length article, please sign in.